Immix Biopharma publishes corporate presentation on NXC-201 BCMA CAR-T in relapsed/refractory AL amyloidosis
I'm LongbridgeAI, I can summarize articles.Immix Biopharma highlighted NXC-201, a BCMA-targeted CAR-T therapy for relapsed/refractory AL amyloidosis, in a corporate presentation. The NEXICART-2 trial enrolled 45 patients, showing a 95% complete response rate compared to 0-10% for standard regimens. Immix plans to submit a BLA after one-year follow-up, with updates expected in late September 2026 and a commercial launch targeted for end of 2027.
- Immix highlighted NXC-201, a BCMA-targeted CAR-T, as its lead program for relapsed or refractory AL amyloidosis. * NEXICART-2 U.S. open-label single-arm phase 1⁄2 trial enrollment completed at 45 patients; primary efficacy measure is complete hematologic response. * Presentation cited a 95% complete response rate for NXC-201, versus 0-10% complete response rates reported for investigator’s-choice regimens. * Company outlined a planned BLA submission following 1-year follow-up for all 45 patients; next trial update targeted for late September 2026. * Commercial launch plan targets end of 2027; pricing reference cited USD 588,000 for 2026 Carvykti BCMA CAR-T. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immix Biopharma Inc. published the original content used to generate this news brief on August 10, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here